Abstract: The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.

Abstract: Compositions and methods for treating a cytokine release syndrome such as chimeric antigen receptor T-cell cytokine release syndrome or hemophagocytic lymphohistiocytosis are provided.

Abstract: The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.

Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.

Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.

Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.

Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.

Abstract: The invention includes method, pharmaceutical compositions and uses thereof for treating patients with Papillary Thyroid Carcinoma (PTC) using a Platelet Derived Growth Factor Receptor Alpha (PDGFRA) inhibitor. The PDGFRA inhibitor is preferably an antibody specific to PDGFRA and causes an increase in the sensitivity level of PTC cells to radioiodine treatment. Moreover, the antibody can be used in combination with other PDGFRA inhibitors such as tyrosine kinase inhibitors and RNA interference molecules.

Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.

Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.

Abstract: The present invention provides a mutated antibody of the fully humanized HER2 antibody GB235-019, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the mutated antibody are respectively SEQ ID NO: 10, SEQ ID NO: 2; SEQ ID NO: 11, SEQ ID NO: 2; or SEQ ID NO:12, SEQ ID NO:2. The mutated antibody has the ability to specifically bind to human HER2 antigen, similar to the GB235-019 antibody. They can also be used in combination with additional HER2 positive tumor therapeutic agents for treating HER2 positive tumor, weakly positive tumor or negative tumor.

Abstract: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

Abstract: The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13 -mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).

Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human FLT3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Abstract: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.

Abstract: The invention relates to antibody molecules which bind pSYK, and methods for using the same for diagnosis, prognosis, to select patients for treatment with a SYK-targeted therapy, or evaluate the pharmacodynamic profile of a SYK-targeted therapy.

Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Abstract: Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein i) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations H310A, H433A and Y436A, or ii) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations L251D, L314D and L432D, or iii) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations L251S, L314S and L432S.

Abstract: Provided are a branched multi-peptide composition and a vaccine including the same. The branched multi-peptide vaccine according to the present invention is easy to be produced and utilized, thereby being easily applied to the treatment, and is capable of maintaining stable reaction in vivo, such that it is expected that the branched multi-peptide vaccine according to the present invention acts as an effective vaccine. Further, for the tumor antigen peptide, the present invention may select an antigen that is largely expressed in a malignant brain tumor. In addition, from now on, it is expected that tumor antigens having a large expression level may be analyzed depending on tumor characteristics of an individual patient, such that the branched multi-peptide vaccine according to the present invention may be utilized for producing personalized branched peptides and vaccines using the same.

Abstract: The present application relates to cellulose nanocrystals and other anionic carbohydrates and methods of preparation thereof. Specifically, in certain embodiments, the cellulose nanocrystals are modified using ion exchange technology to yield thermally stable or task-specific, dispersible cellulose nanocrystals.

Abstract: The present invention provides an effective method for fractionating rubber particles in natural rubber latex by particle size, and effective methods for transporting or preserving rubber particles. The present invention relates to a method for fractionating rubber particles in natural rubber latex by particle size, the method including centrifuging natural rubber latex in at least four stages at forces of 800 to 3,000×g, 6,500 to 10,000×g, 17,000 to 22,000×g, and 40,000 to 60,000×g to fractionate rubber particles. The present invention also relates to methods for transporting or preserving rubber particles, the methods including the steps of adding a buffer solution and an antioxidant to natural rubber latex or rubber particles fractionated from natural rubber latex; and freezing a mixture prepared in the above step.

Abstract: Provided are: an alkoxysilyl group-containing hydrogenated block copolymer produced by introducing an alkoxysilyl group into a hydrogenated block copolymer that is obtained by hydrogenating 90% or more of unsaturated bonds of a block copolymer that includes at least two polymer blocks [A] and at least one polymer block [B], the polymer block [A] including a repeating unit derived from an aromatic vinyl compound as a main component, the polymer block [B] including a repeating unit derived from a linear conjugated diene compound as a main component, and a ratio (wA:wB) of a weight fraction wA of the polymer block [A] in the block copolymer to a weight fraction wB of the polymer block [B] in the block copolymer being 20:80 to 60:40; a method for producing the same; a solar cell element encapsulating material; a sheet; a laminated sheet; a multilayer sheet; and a method for encapsulating a solar cell element.

Abstract: A polymer having a long chain branching content peaking at greater than about 20 long chain branches per million carbon atoms, and a polydispersity index of greater than about 10 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. A polymer having a long chain branching content peaking at greater than about 8 long chain branches per million carbon atoms, a polydispersity index of greater than about 20 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. A polymer having a long chain branching content peaking at greater than about 1 long chain branches per chain, and a polydispersity index of greater than about 10 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution.

Abstract: An object of the invention is to provide polymerizable compounds having excellent optical characteristics and suited as materials for optically anisotropic articles, compositions containing the polymerizable compounds, polymers obtained by polymerising the polymerizable compounds, optically anisotropic articles formed of the polymers, and liquid crystal display devices including the optically anisotropic articles.

Abstract: A process for preparing a stabilized fabricated article from a polyolefin resin, the process includes incorporating functional groups in the polyolefin resin thereby yielding a polyolefin resin having crosslinkable functional groups. The polyolefin resin having crosslinkable functional groups is converted to a fabricated article. The fabricated article is chemically crosslinked thereby yielding a crosslinked fabricated article. The crosslinked fabricated article is stabilized in an oxidizing environment at an elevated temperature. The stabilized fabricated article thus produced can be prepared as a carbonaceous article by heating the stabilized fabricated article in an inert environment.

Abstract: An object of the invention is to provide compositions which have low-temperature heat sealing properties, are free from stickiness, may achieve a heat seal strength controlled within a certain definite range when heat sealing takes place at low temperatures, have small changes in heat seal strength with time, and are such that in the packaging applications, the strength required to open the packages may be easily controlled within a certain definite range, and high-performance packages may be designed. The invention resides in a 1-butene.?-olefin copolymer composition including 99 to 1 parts by mass of at least one olefin polymer (X) selected from propylene polymers (X-1) and ethylene polymers (X-2), and 1 to 99 parts by mass of a 1-butene.?-olefin copolymer (Y) containing 0.1 to 30 mol % of one or more ?-olefins selected from ?-olefins and having a molecular weight distribution (Mw/Mn) of 1.0 to 3.5 [wherein the total of (X) and (Y) in the composition is 100 parts by mass].

Abstract: By controlling the ratio of catalyst components or the type of activator the homogeneity of a polymer produced using a single site catalyst may be improved.

Abstract: The various embodiments of the invention provide, a magnesium titanium polymerization procatalyst, methods for making and using the same.

Abstract: Catalyst system for producing ethylene copolymers in a high temperature solution process, the catalyst system comprising (i) a metallocene complex of formula (I) wherein M is Hf X is a sigma ligand, L is a bridge of the formula —SiR82—, wherein each R8 is independently a C1-C20-hydrocarbyl, tri(C1-C20-alkyl)silyl, C6-C20-aryl, C7-C20-arylalkyl or C7-C20-alkylaryl n is 0, 1 or 2 R1 and R1? are the same or can be different and can be a linear or branched C1-C6-alkyl group, R2 and R2? are the same or are different and are a CH2—R9 group, with R9 being H or linear or branched C1-C6-alkyl group R5 and R5? are the same or are different and can be H or a linear or branched C1-C6-alkyl group or a OR group, wherein R is a C1-C6-alkyl group R6 and R6? are the same or are different and can be H or a C(R10)3 group, with R10 being the same or different and R10 can be H or a linear or branched C1-C6-alkyl group or R5 and R6 and/or R5? and R6? taken together form an unsubstituted 4-7 membered ring condensed to the benzene r

Abstract: Catalyst system for producing ethylene copolymers in a high temperature solution process, the catalyst system comprising (i) a metallocene complex of formula (I) wherein M is Hf or Zr X is a sigma ligand, L is a bridge of the formula —SiR82—, wherein each R8 is independently a C1-C20-hydrocarbyl, tri(C1-C20-alkyl)silyl, C6-C20-aryl, C7-C20-arylalkyl or C7-C20-alkylaryl n is 0, 1 or 2 R1 and R1? are the same or can be different and can be a linear or branched C1-C6-alkyl group, R2 and R2? are the same or are different and are a CH2—R9 group, with R9 being H or linear or branched C1-C6-alkyl group R5 and R5? are the same or are different and can be H or a linear or branched C1-C6-alkyl group or a OR group, wherein R is a C1-C6-alkyl group R6 and R6? are the same or are different and can be H or a C(R10)3 group, with R10 being the same or different and R10 can be H or a linear or branched C1-C6-alkyl group or R5 and R6 and/or R5? and R6? taken together form an unsubstituted 4-7 membered ring condensed to the ben

Abstract: The invention provides a method for making a fluoropolymer and a method for preparing a fluorinated surfactant.

Abstract: A polymer compound containing a repeating unit shown by the formula (1c) and one or more repeating units selected from a repeating unit shown by the formula (2) and a repeating unit shown by the formula (3), wherein Mb+ represents a sulfonium cation shown by the formula (a) or an iodonium cation shown by the formula (b), This polymer compound is suitable as a base resin of a resist composition capable of forming a resist film that allows pattern formation with extremely high resolution, small LER, and excellent rectangularity.

Abstract: The present invention provides a saponified ethylene-vinyl ester copolymer product from which a film having reduced fish eyes can be obtained and a method for producing an ethylene-vinyl ester copolymer that is a precursor thereof. At the time of producing the ethylene-vinyl ester copolymer, as a vinyl ester monomer, the oxygen concentration at storage and/or transportation is adjusted to from 2 to 8 ppm and the oxygen concentration at polymerization is adjusted to less than 2 ppm.

Abstract: A method for manufacturing a polymer of which structure is exactly controlled is disclosed.

Abstract: The present invention relates to a method for making a direct emulsion of a copolymer in water, characterized in that it comprises the polymerization of at least, expressed as a percentage by weight of each of the monomers based upon the total weight of the monomers: a) 10 to 80% by weight of methacrylic acid and, optionally, of acrylic acid; b)15 to 80% by weight of at least one non-ionic vinyl monomer; c) 0.05 to 9.5% by weight of 2-acrylamido-2-methylpropane sulfonic acid or a salt thereof; d) 0.5 to 30% by weight of at least one monomer containing at least one hydrophobic group; and e) 0.01 to 5% by weight of at least one crosslinking monomer; said polymerization being carried out in the presence of at least one surfactant. It also relates to the corresponding new copolymer emulsion in water, a method for thickening an aqueous composition comprising such an emulsion of copolymer and to an aqueous composition comprising such a copolymer emulsion.

Abstract: A copolymer is prepared by the polymerization of monomers that include an ultraviolet absorbing monomer, and a base-solubility-enhancing monomer. The copolymer is useful for forming a topcoat layer for electron beam and extreme ultraviolet lithographies. Also described are a layered article including the topcoat layer, and an associated method of forming an electronic device.

Abstract: A process for preparing water-absorbing polymer beads with high permeability by polymerizing droplets of a monomer solution, comprising monomers bearing acid groups, in a gas phase surrounding the droplets, wherein the monomer solution comprises polyvalent cations and the polymer beads have a mean diameter of at least 150 ?m.

Abstract: The present disclosure provides for new photoalignment (co)polymer materials which demonstrate improved adhesion to a substrate. The (co)polymeric structure includes at least one photochemically active chromophore and at least one adhesion promoter group. Articles of manufacture, optical elements, ophthalmic elements and liquid crystal cells which include at least one photoalignment layer made from the photoalignment (co)polymer materials and methods for formation are also disclosed.

Abstract: The present invention addresses the problem of providing a cross-copolymer having excellent flexibility, heat resistance, cold resistance and mechanical properties. The present invention also addresses the problem of providing a resin composition which is prepared using the cross-copolymer, has excellent compatibility with polyolefin resins and aromatic resins, and has excellent flexibility, heat resistance and cold resistance.

Abstract: Provided is a graft copolymer (A) obtainable by graft-polymerizing, in the presence of 30 to 80 parts by mass of an ethylene-based polymer (a), an aromatic vinyl-based monomer (b) and, if necessary, another vinyl-based monomer (c) copolymerizable with the aromatic vinyl-based monomer (b) in a total amount of 20 to 70 parts by mass (provided that the sum of the components (a), (b) and (c) is 100 parts by mass), in which the ethylene-based polymer (a) has a density of 0.900 g/cm3 or more and less than 0.966 g/cm3, a number average molecular weight of 10,000 to 50,000, and a molecular weight distribution of 5 to 15, and the proportion of the ethylene-based polymer (a) molecules having a molecular weight of 10,000 or less is 5.5% or more.

Abstract: Methods are provided for surface-modifying a rubber vulcanizate or a thermoplastic resin. The methods allow these objects to have a chemically fixed surface layer that exhibits not only low adsorption or selective adsorption properties with respect to proteins and cells, but also excellent durability, instead of having a coating which has drawbacks such as reduction in properties due to separation or peeling of the coating. Included is a method for surface-modifying an object made of a rubber vulcanizate or a thermoplastic resin, the method including: a step 1 of forming polymerization initiation points on the surface of the object; and a step 2 of radically polymerizing a hydrophilic monomer starting from the polymerization initiation points by irradiation with UV light having a wavelength of 300 to 400 nm in the presence of an alkali metal salt to grow polymer chains on the surface of the object.

Abstract: An amphiphilic block copolymer comprises a poly(phenylene ether) block or a poly(phenylene ether) copolymer block and a hydrophilic block or graft. A method of making the amphiphilic block copolymer comprises polymerization of a hydrophilic ethylenically unsaturated monomer in the presence of poly(phenylene ether) or a poly(phenylene ether) copolymer to make the amphiphilic block copolymer. A porous asymmetric membrane comprises a poly(phenylene ether) or poly(phenylene ether) copolymer, and the amphiphilic block copolymer comprising a poly(phenylene ether) block or a poly(phenylene ether) copolymer block, and a hydrophilic block or graft. The porous asymmetric membrane is made by phase-inversion of a dope solution of the poly(phenylene ether) or poly(phenylene ether) copolymer and the amphiphilic block copolymer in a coagulation bath.

Abstract: A block copolymer useful in electron beam and extreme ultraviolet photolithography includes a first block with units derived from a base-solubility-enhancing monomer and an out-of-band absorbing monomer, and a second block having a low surface energy. Repeat units derived from the out-of-ban absorbing monomer allow the copolymer to absorb significantly in the wavelength range 150 to 400 nanometers. When incorporated into a photoresist composition with a photoresist random polymer, the block copolymer self-segregates to form a top layer that effectively screens out-of-band radiation.

Abstract: The present invention provides a sheet-forming body containing a thiourethane bond-having compound and a thiol group-having compound, wherein, in an IR absorption spectrum thereof, the ratio of the peak intensity A of the absorption peak based on the carbonyl group in the thiourethane bond to the peak intensity B of the absorption peak based on the thiol group (A/B) is 20 or more and 250 or less. Using the sheet-forming body, rubber members, especially vulcanized rubber members can be strongly bonded, and the sheet-forming body and an adhesive sheet, which are excellent in handleability and workability, and a laminate produced by bonding rubber layers using the sheet-forming body are provided.

Abstract: The invention relates to a polyurethane-polyurea binder which contains specific silicones or polyvinyl pyrrolidones and which is suitable for the manufacture of press materials from organic and/or inorganic materials, to the corresponding use of said binders and to the press materials manufactured using the specific binders.

Abstract: Semi-crystalline polyesters from isoidide and 2,5-furandicarboxylic acid are disclosed, as well as semi-crystalline copolyesters from isoidide and a minor amount of either 1,4-butanediol or 2,3-butanediol with 2,5-furandicarboxylic acid, together with processes for making high molecular weight materials by melt polymerization providing a semi-crystalline polymer then performing solid state condensation on the semi-crystalline polymer.

Abstract: The present invention relates to a polyester resin with excellent solubility in generic solvents, especially with excellent solubility at a temperature of 0° C. or lower. According to the present invention, by using the polyester resin with excellent solubility in generic solvents, solubility at a lower temperature, especially the solubility at a temperature of 0° C. or lower, is enhanced, making it easier to prepare paints, coatings and the like. The polyester resin related to the present invention contains 0.05 to 0.5 mol of an isosorbide-derived structural unit and 0.015 to 0.4 mol of a trihydric or higher alcohol-derived structural unit relative to 1 mol of a polycarboxylic acid-derived structural unit.